Insulin-like growth factors and cancer

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.

Oncogene·2013

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

BMC cancer·2012

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

Endocrinology·2010

The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma.

Oncogene·2007

IGF1R signalling and its inhibition.

Endocrine-related cancer·2007

Why early pathology input matters in biologically rich cancer trials.

British journal of cancer·2026

ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.

British journal of cancer·2026

Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

British journal of cancer·2026

On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort.

British journal of cancer·2026

Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.

British journal of cancer·2026

The role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials.

British journal of cancer·2026

Exercise interventions remodel the aging microenvironment to improve prognosis in older patients with cancer.

Frontiers in immunology·2026

Dynamic junction remodeling and transient vascular disruption during cancer cell extravasation across the blood-brain barrier.

Frontiers in cell and developmental biology·2026

RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.

International journal of surgery (London, England)·2026

CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

Clinical and translational medicine·2026

CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.

Asia-Pacific journal of clinical oncology·2026

Closing the gap in aging science: unlocking the potential of nanoparticles in senescence therapy.

Biogerontology·2026

Related Experiment Videos

Insulin-like growth factors and cancer

Related Concept Videos

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma.

IGF1R signalling and its inhibition.

Why early pathology input matters in biologically rich cancer trials.

ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.

Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort.

Risk prediction model for brain metastasis risk among patients diagnosed with primary gastrointestinal cancers.

The role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials.

Exercise interventions remodel the aging microenvironment to improve prognosis in older patients with cancer.

Dynamic junction remodeling and transient vascular disruption during cancer cell extravasation across the blood-brain barrier.

RUNX3+ basal-like malignant cells: architects of an immunosuppressive microenvironment in bladder cancer: a comprehensive bioinformatics analysis of single-cell and spatial transcriptomics.

CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.

Closing the gap in aging science: unlocking the potential of nanoparticles in senescence therapy.

Related Experiment Videos

Insulin-like growth factors and cancer

Related Concept Videos

Related Articles